Combination of PDL-1 and PARP inhibition in an unselected population with metastatic castrate-resistant prostate cancer (mCRPC).Fatima Karzai, Jung‐Min Lee, Ravi A. Madan et al.|Journal of Clinical Oncology|2017Cited by 22
Relationship of DNA methylation to mutational changes and transcriptional organization in fusion‐positive and fusion‐negative rhabdomyosarcomaWenyue Sun, Frederic G. Barr, Bishwanath Chatterjee et al.|International Journal of Cancer|2018Cited by 21
A phase II study of the anti-programmed death ligand-1 antibody durvalumab (D; MEDI4736) in combination with PARP inhibitor, olaparib (O), in metastatic castration-resistant prostate cancer (mCRPC).Fatima Karzai, Jung‐Min Lee, Ravi A. Madan et al.|Journal of Clinical Oncology|2017Cited by 20
Expression of the muscle-associated gene MYF6 in hairy cell leukemiaEvgeny Arons, Robert J. Kreitman, Daniel C. Edelman et al.|PLoS ONE|2020Cited by 8